Pliant Therapeutics, INC Form 4 insider transactions

Pliant Therapeutics' General Counsel and Corporate Secretary, Mike Ouimette, received 35,000 shares of common stock and options to purchase 70,000 shares, according to a recent SEC filing.

Hans Hull, Chief Business Officer of Pliant Therapeutics, reported the acquisition of restricted stock units and stock options, along with adjustments to his beneficial ownership.

Pliant Therapeutics' Chief Medical Officer, Eric Lefebvre, received stock units and options, as detailed in a recent SEC Form 4 filing.

Pliant Therapeutics' Chief Financial Officer, Keith Cummings, received stock and option awards as part of his compensation, according to a recent SEC filing.

Pliant Therapeutics CEO, Bernard Coulie, acquired 162,500 shares of common stock and 325,000 stock options, while also reporting indirect ownership of 409,317 shares through a family trust.

Pliant Therapeutics CEO, Bernard Coulie, sold 52,419 shares of common stock to cover tax liabilities related to vesting restricted stock units.

Pliant Therapeutics' Chief Financial Officer, Keith Lamont Cummings, sold 20,148 shares of common stock to cover tax liabilities related to vesting restricted stock units.

Pliant Therapeutics' Chief Business Officer, Hans Hull, sold 15,936 shares of common stock at an average price of $11.2011 to cover tax liabilities related to vesting restricted stock units.

Pliant Therapeutics' Chief Medical Officer, Eric Lefebvre, sold 18,478 shares of common stock to cover tax liabilities related to vesting restricted stock units.

A Pliant Therapeutics executive, Lily Cheung, sold 3,740 shares of common stock to cover tax obligations related to vesting restricted stock units.

Pliant Therapeutics' General Counsel, Mike Ouimette, sold a total of 23,500 shares of common stock in two transactions under a pre-arranged 10b5-1 trading plan.

Eric Lefebvre, Chief Medical Officer of Pliant Therapeutics, sold 12,319 shares of common stock to cover withholding tax obligations related to vesting performance-vested stock units.

Hans Hull, Chief Business Officer of Pliant Therapeutics, sold 9,900 shares of common stock to cover withholding tax liabilities related to vesting performance-vested stock units.

Keith Lamont Cummings, CFO of Pliant Therapeutics, sold 10,911 shares of common stock on July 10, 2024, to cover withholding tax obligations related to vesting stock units.

Pliant Therapeutics CEO Bernard Coulie sold 38,710 shares of common stock on July 10, 2024, to cover withholding tax liabilities related to the vesting of performance-vested stock units.

Mike Ouimette, General Counsel of Pliant Therapeutics, sold 7,656 shares of common stock to cover withholding tax liabilities related to vesting stock units.

Eric Lefebvre, Chief Medical Officer of Pliant Therapeutics, acquired 24,063 shares of common stock on July 9, 2024, following the achievement of performance criteria related to the company's total shareholder return.

Hans Hull, Chief Business Officer of Pliant Therapeutics, reports the vesting of performance-based stock units and acquisitions through an employee stock purchase plan.

Keith Lamont Cummings, CFO of Pliant Therapeutics, acquired 21,313 shares of common stock on July 9, 2024, following the achievement of a performance milestone related to the company's total shareholder return.

Pliant Therapeutics' CEO, Bernard Coulie, acquired 75,625 shares of common stock after the achievement of performance criteria related to the company's total shareholder return.

Mike Ouimette, General Counsel & Corp. Sec'y of Pliant Therapeutics, acquired 14,954 shares of common stock following the achievement of a performance milestone related to total shareholder return.

Director Thomas McCourt acquired 26,764 shares of Pliant Therapeutics via an option grant on June 13, 2024.

Director Katharine Knobil reports acquisition of stock options in Pliant Therapeutics.

Director Hoyoung Huh acquired 26,764 shares of Pliant Therapeutics (PLRX) through a stock option grant on June 13, 2024.

Director David E I Pyott acquired stock options in Pliant Therapeutics, Inc. on June 13, 2024.

Director Smital Shah acquired stock options in Pliant Therapeutics, according to a recent SEC filing.

Director Darren S. Cline of Pliant Therapeutics acquires stock options, signaling potential confidence in the company's future.

Director Gayle A. Crowell reports receiving a stock option grant from Pliant Therapeutics, Inc.

Director Suzanne Bruhn acquired 26,764 stock options in Pliant Therapeutics on June 13, 2024, at an exercise price of $13.06.

Director John T. Curnutte acquired 26,764 shares of Pliant Therapeutics through an option grant on June 13, 2024.